Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Natera, Inc. (“Natera”) (NASDAQ: NTRA) common stock between February 27, 2020 and March 8, 2022, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts concerning two of Natera’s core products, Prospera, a non-invasive kidney transplant rejection test, and Panorama, its non-invasive prenatal test. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Panorama, was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants’ false and misleading claims about Natera’s technology, Natera was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, Defendants’ statements about Natera’s business, operations, and prospects lacked a reasonable basis t all relevant times.
Current Status of Case:
On March 21, 2025, the Court granted Lead Plaintiffs’ Motion for Class Certification, and on March 13, 2026, the Court approved the class certification notice. This action is in the discovery phase and is ongoing.
For more information on the case and the Motion for Class Certification, please visit our website at https://www.ktmc.com/featured-case/natera-inc.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.